Lipid metabolic phenotypes in pediatric Prader–Willi syndrome versus non-syndromic obesity: conventional lipids and emerging lipidomic evidence
Frontiers in Endocrinology · 20.11.2026 · 17
DOI: 10.3389/fendo.2026.2000348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 20.11.2026. Verfasst von Xinyu Ma und 5 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prader–Willi syndrome (PWS) combines genetically determined hyperphagia, altered body composition, growth hormone (GH) axis abnormalities, and progressive obesity, creating a metabolic context that differs from non-syndromic obesity (NSO). Whether PWS confers a uniformly more atherogenic lipid phenotype remains uncertain. This critical narrative review synthesizes pediatric evidence on conventional lipids, lipidomic remodeling, and their relationships with adiposity, insulin sensitivity, inflammation, body composition, genotype, and recombinant human GH (rhGH) exposure. More adverse conventional lipid profiles have been reported mainly in cohorts without rigorous matching for adiposity or body composition; these findings cannot be assumed to represent an independent syndrome effect. In contrast, a GH-naive cohort with similar BMI to NSO controls showed markedly higher lipoprotein(a) in PWS but broadly similar triglyceride, HDL-C, and LDL-C concentrations. Lipidomic evidence is more limited: a single pediatric discovery cohort reported lower total phosphatidylcholine and lysophosphatidylcholine concentrations in PWS than in NSO and normal-weight controls, together with exploratory PWS-specific associations between selected phospholipid species, BMI, and gut microbial taxa. These molecular findings have not yet been independently replicated and should not be interpreted as a validated diagnostic or prognostic signature. Overall, conventional lipid assessment remains the clinical standard and should be interpreted alongside adiposity, lean mass, pubertal stage, and rhGH exposure. Lipidomics currently provides mechanistic and hypothesis-generating information rather than a PWS-specific clinical risk-stratification tool.
Zitieren
APA
Ma, X., Wang, K., Pi, Y., Zhang, Y., Zhang, H., & Xing, Y. (2026). Lipid metabolic phenotypes in pediatric Prader–Willi syndrome versus non-syndromic obesity: conventional lipids and emerging lipidomic evidence. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2000348
Vancouver
Ma X, Wang K, Pi Y, Zhang Y, Zhang H, Xing Y. Lipid metabolic phenotypes in pediatric Prader–Willi syndrome versus non-syndromic obesity: conventional lipids and emerging lipidomic evidence. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2000348
BibTeX
@article{Ma2026,
author = {Ma, Xinyu and Wang, Kaixi and Pi, Yalei and Zhang, Yanan and Zhang, Huifeng and Xing, Yutong},
title = {Lipid metabolic phenotypes in pediatric Prader–Willi syndrome versus non-syndromic obesity: conventional lipids and emerging lipidomic evidence},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.2000348}
}
EUVIMED